Formed in 2007, biOasis is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of technologies for the diagnosis and treatment of central nervous system (“CNS”) diseases & disorders. The World Health Organization declared that CNS disorders represent the major medical challenge of the 21st Century. Valued at more than US $98 billion, the CNS market segment is the 2nd largest category in the pharmaceutical industry and is growing at approximately 8% per annum. Despite the large and growing market, most CNS diseases are difficult or impossible to treat due to the blood-brain barrier (“BBB”). The BBB protects the brain by preventing almost all foreign substances from entering. As a result over 95% of known drugs do not cross the BBB. biOasis is currently focused on two commercialization programs that exploit the physiological and biochemical properties of proteins & peptides that are able to cross the BBB.
biOasis is a publically traded company that trades on the TSX-Venture exchange under the symbol BTI.
Rob Hutchison, Chairman & CEO
David Clark, C, CFO
Dr. Chris Fibiger: Chris is the former head of Neuroscience at Amgen and former VP of Neuroscience and LRL Europe at Eli Lilly and Company. Chris recently retired from Biovail Laboratories where he was their Chief Science Officer. +
Dr. Terry Pearson: Terry is a professor of Biochemistry and Microbiology at the University of Victoria. Following postdoctoral work in the laboratory of Nobel Laureate Dr. Sydney Brenner, he was involved in the early stages of the development of monoclonal antibody technology. +
Mr. Michael Hutchison QC, LLB: Mike is a partner at the firm of Smith Hutchison and acts for biOasis Advanced Technologies Inc. +
Commercial Programs:
Cognitest™ is a blood test designed to identify patients afflicted with Alzheimer’s disease. Proof of concept is recognized in the peer-reviewed literature (Kim, D.K. et al., Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 25(1):84-90, 2001). The Company is developing this product with the assistance of UK based Fleet BioProcessing. more...
Transcend™ is a carrier for delivery of therapeutic agents across the BBB. biOasis has performed proof of concept studies for Transcend™ and has demonstrated the delivery of drugs across the BBB (Karkan, D. et al. 2008 A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier. PLoS ONE 3(6): e2469.doi:10.1371/journal.pone.0002469). By commercializing Transcend™ biOasis will enable the routine treatment of a variety of clinically challenging CNS conditions. To reduce commercial risk and decrease time to regulatory approval, our initial focus is on linking Transcend™ to drugs that have already been approved by regulatory agencies for non-CNS indications. Our business strategy for Transcend also includes the delivery of novel biologics (proteins & peptides) to treat CNS diseases for which there are limited therapeutic option.. The biOasis business model is based on the aggressive out-licensing of Transcend™ to ensure broad use within the industry.
 Mr. Rob Hutchison, CEO & ChairmanRob is the former founder, CEO & Chief Scientist of eCharge Corporation. Rob has extensive experience in the development and commercialization of technologies and has vast intellectual property experience.  Dr. Bob Cory, VP Business DevelopmentBob has over 15 years of business and corporate development experience in the biopharmaceutical industry and has lead strategic partnering transactions with a number of multi-national pharmaceutical and biotech companies.  Dr. Reinhard Gabathuler VP R&DReinhard has over 25 years experience in research in academia and in early stage development companies (start-ups) and a broad knowledge of scientific research from Plant Biochemistry to Immunology, Oncology and Neurology. He has been very successful in a research results driven environment and is a strong leader with planning and interpretation skills acquired in early stage biotechnology companies.  Dr. Tim Vitalis, Senior Scientist Tim has more than 15 years experience in biotechnology research and development. His professional experience spans both discovery research in academic organizations and biotechnology product development in the private sector. Specific scientific expertise includes blood brain barrier transport, immunology, oncology, infectious disease, and respiratory pathology.  Mr. David Clark CA, CFO & DirectorDavid has extensive experience as a CFO for a number of public companies. David has managed the process of taking company’s public, mergers and acquisitions, and the raising of public and private equity and debt. | |||||||||
